Inactive Instrument

All News Ritter Pharmaceuticals Inc Nasdaq

Equities

US7678361095

All News

Unlock all the news: Be the first to know and act before the market!

Qualigen Therapeutics, Inc. Announces Board Changes	Jul. 15	CI
Qualigen Therapeutics, Inc. announced that it has received $2 million in funding	Jul. 07	CI
Qualigen Therapeutics, Inc. announced that it expects to receive $2 million in funding	Jul. 04	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Jul. 02	CI
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination	May. 30	AQ
Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	Apr. 16	CI
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting	Apr. 10	AQ
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting	Apr. 09	AQ
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Qualigen Therapeutics, Inc. Enters into A Termination Agreement with Pan-RAS Holdings, Inc	Mar. 28	CI
Qualigen Therapeutics, Inc. announced that it has received $0.55 million in funding from Alpha Capital Anstalt	Feb. 26	CI
Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt	Feb. 25	CI
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc	Feb. 22	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023	Nov. 14	AQ
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	Nov. 07	AQ
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	Nov. 07	CI
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer	23-10-23	AQ
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023	23-09-27	AQ
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors	23-08-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Ritter Pharmaceuticals Inc Nasdaq

Equities

US7678361095

All News

Filters